drugset / Trial / NCT01402817
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Phase 2
Terminated
19 enrolled
Indiana University
Pfizer · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study to determine if adults and children with neurofibromatosis type 1 who have plexiform tumors given Sutent® respond to this drug therapy.
Timeline
- Start
- 2012-03
- Primary completion
- 2015-10
- Completion
- 2018-02-14
Outcome
Outcome not reported
Stopped: “1 patient died of uncertain cause but possibly related to drug.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 10 mg/m2 | Oral |
| Subject | Sunitinib | Small molecule | 15 mg/m2 | Oral |
| Subject | Sunitinib | Small molecule | 25 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |